GFAP and Alzheimer disease: Plasma GFAP and pTau231 were the only two biomarkers with significant differences (global p < 0.05) in concentration across all comparisons i.e.: postmortem-confirmed clinical diagnosis and severity of AD neuropathology, including CERAD and Braak scores.